Skip to Main Content

Author Details

Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
2000
42
20
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37369443Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.Can J Surg2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
34162658Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2021
32277480ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.Int J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
31001917Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.Cancer Med2019
31239549A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.Mod Pathol2019
31227223PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.Gynecol Oncol2019
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
30013673Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.J Circ Biomark2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
31360864Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer.JNCI Cancer Spectr2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
29367611Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.Sci Rep2018
29531130Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev2018
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
28346442Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet2017
28342318Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.Transl Oncol2017
29029385Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.Oncotarget2017
29049607Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.JAMA Oncol2017
26882065Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.Br J Cancer2016
27798111The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.Hum Mol Genet2016
27444035Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.Gynecol Oncol2016
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26152742Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Clin Cancer Res2015
25316818Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin Cancer Res2014
21423607Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One2011
18980987Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.Clin Cancer Res2008
12481425Cell proliferation in the normal mouse mammary gland and inhibition by phenylbutyrate.Mol Cancer Ther2002
11106251Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.Clin Cancer Res2000
  • 1 - 42 of 42

Recommended Authors

Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 7
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 9
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 5
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 2
Myriam Kossai
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 1
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 1
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 39
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 30
Brigitte L Th??riault
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2004
Number of shared co-authors 0
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Karin Jirstr??m
Lund University
Career Start Year 2003
Number of shared co-authors 5
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 15
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 4
Blaise A Clarke
University of Toronto.
Career Start Year 2001
Number of shared co-authors 50
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 1
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 24
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 30
Aparna A Kamat
Houston Methodist Hospital
Career Start Year 2000
Number of shared co-authors 1
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 4
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 5
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 3
Paulette Mhawech-Fauceglia
University of Southern California
Career Start Year 1995
Number of shared co-authors 12
Denise C Connolly
Fox Chase Cancer Center
Career Start Year 1993
Number of shared co-authors 10
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 57
Rosemarie Schmandt
The University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 4
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 36
Patricia A Shaw
Princess Margaret Cancer Centre, University Avenue
Career Start Year 1990
Number of shared co-authors 51
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 93
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 42
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 3

Collaborators

Anna DeFazio
Westmead Hospital
Co-authored papers 42
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 23
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 23
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 20
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 20
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 18
Stacey J Winham
Mayo Clinic
Co-authored papers 17
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 17
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 17
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 16
Martin K??bel
University of Calgary
Co-authored papers 16
David G Huntsman
University of British Columbia
Co-authored papers 16
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 16
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 15
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 14
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 14
Alison Brand
Westmead Hospital
Co-authored papers 14
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 14
Raghwa Sharma
Westmead Hospital
Co-authored papers 14
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 13
Andrew Berchuck
Duke School of Medicine
Co-authored papers 13
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 13
Michael E Carney
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 12
Jan Lubinski
Pomeranian Medical University
Co-authored papers 12
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 12
Michael S Anglesio
University of British Columbia
Co-authored papers 12
Jennifer Alsop
University of Cambridge
Co-authored papers 12
Linda E Kelemen
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 12
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 12
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 12
Release 1.2